Kropotova Alexandra 4

What Happened
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics (SABS), had 988 shares of common stock withheld on March 24, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs). The transaction is coded F (tax withholding); no open‑market sale price is reported (N/A). This is a routine tax withholding related to compensation vesting, not a market purchase.

Key Details

• Transaction date: 2026-03-24; Form 4 filed: 2026-03-25 (timely filing shown).
• Transaction type/code: F = shares withheld to satisfy tax withholding on RSU vesting.
• Shares withheld/disposed: 988 shares (no cash/price reported).
• Reported holdings after transaction: 34,553 shares of Common Stock beneficially owned and 8,743 shares subject to future vesting under RSUs (per filing footnote).
• Relevant footnotes from the filing: F1 — shares withheld to satisfy tax withholding on RSU vesting; F2 — holdings include 34,553 shares plus 8,743 RSUs still subject to vesting; F3 — each RSU equals a contingent right to one share.
• No 10b5‑1 plan or sale reported; this is not an open‑market transaction and should be treated as administrative/tax‑related.

Context
RSUs are compensation that convert to shares when vested; companies commonly withhold a portion of shares to cover tax liabilities. Such withholdings are routine and do not necessarily indicate insider sentiment about the stock. Purchases by insiders tend to carry more weight for signaling than tax‑withholding dispositions.